MetaCap

Globus Medical (GMED) vs Insulet (PODD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Globus Medical (GMED) has outperformed Insulet (PODD) over the past year, losing 22.2% versus a loss of 59.8%. Over five years, GMED leads with a +4.6% price change compared with -54.9% for PODD. Insulet is the larger company by market cap ($9.24 billion vs $8.86 billion), about 1.0 times the size.

On valuation, Globus Medical trades at a lower forward P/E (12.5x vs 16.8x for Insulet). Globus Medical converts more of its revenue into profit, with a net margin of 18.3% versus 9.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GMED-22.24%PODD-59.79%
+16%-24%-64%
Nov 21, 20251 yearNov 20, 2026
GMED-1.09%PODD-55.76%
+46%-8%-61%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GMED versus PODD key metrics
MetricGMEDPODD
Share price$66.89$133.17
Market cap$8.86B$9.24B
1-day change-2.49%-2.96%
YTD return-23.39%-53.15%
1-year return-22.24%-59.79%
5-year return+4.60%-54.92%
P/E ratio (TTM)16.4821.76
Forward P/E12.5316.83
EPS (TTM)$4.06$6.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.94B$2.71B
Revenue growth (YoY)+16.65%+30.73%
Net income (latest FY)$537.87M$247.10M
Gross margin67.41%71.63%
Operating margin16.33%17.50%
Net margin18.30%9.12%
52-week high$101.40$342.13
52-week low$66.63$126.40
Distance from 52-week high-34.03%-61.08%
Analyst consensusbuybuy
Avg. price target upside+39.68%+33.60%
Average volume1.63M1.61M
Shares outstanding110.04M69.37M
Employees6,0005,400
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GMED has outperformed PODD by 37.5 percentage points over the past year.
  • Insulet trades at a higher earnings multiple (21.8x vs 16.5x trailing P/E).
  • Globus Medical is more profitable, keeping 18.3 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
  • Insulet grew revenue faster in its latest fiscal year (+30.73% vs +16.65%).

About Globus Medical

GMED stock →

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.

Health Care · Medical/Dental Instruments · 6,000 employees

About Insulet

PODD stock →

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.

Health Care · Medical/Dental Instruments · 5,400 employees

GMED vs PODD FAQ

Which is bigger, Globus Medical or Insulet?

Insulet (PODD) is larger, with a market capitalization of $9.24B compared with $8.86B for Globus Medical (GMED).

Which stock has performed better over the past year, GMED or PODD?

GMED returned -22.24% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, GMED or PODD?

GMED has the lower trailing P/E at 16.5, versus 21.8 for PODD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Globus Medical and Insulet in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons